New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Subscribe To Our Newsletter & Stay Updated
